Conduit Pharmaceuticals INC 10-Q quarterly reports

CDT Equity Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing ongoing net losses, a substantial accumulated deficit, and significant concerns regarding its ability to continue as a going concern.

CDT Equity Inc. reported a net loss for Q1 2026, with significant strategic investments and ongoing liquidity concerns, while also detailing progress in R&D and partnerships.

CDT Equity Inc. reported a net loss of $7.1 million for Q3 2025 and $17.9 million for the nine months ended September 30, 2025, while advancing its data-driven biotech and digital asset treasury management strategy.

CDT Equity Inc. reported a wider net loss for the first half of 2025 despite significant capital raises, as it pivots to an AI-driven biotech development strategy and expands its asset portfolio.

CDT Equity Inc. restated its Q1 2025 financial results due to reclassification errors, reporting increased net losses and significant liquidity concerns, while actively pursuing strategic AI partnerships and asset development.

Conduit Pharmaceuticals reports a net loss of $5.1 million for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern.

Conduit Pharmaceuticals reported a net loss of $6.5 million for Q3 2024 and faces substantial doubt about its ability to continue as a going concern due to significant operating losses and limited cash reserves.

Conduit Pharmaceuticals restated its Q2 2024 financials due to a misclassification of deferred commission payable and is also facing potential delisting from Nasdaq due to its stock price falling below the minimum bid price requirement.

Conduit Pharmaceuticals restated its Q1 2024 financials due to a reclassification error, reporting an increased net loss and operating expenses compared to the same period last year.

Conduit Pharmaceuticals reported its second quarter 2024 financial results, highlighting increased operating expenses and a net loss, while also disclosing ongoing challenges with Nasdaq listing requirements.

Conduit Pharmaceuticals reported a net loss of $3.55 million for the first quarter of 2024, highlighting the company's ongoing need for additional funding to support its operations and research.